Abstracts tagged "Blau syndrome"

Abstract Number: 1269 • 2019 ACR/ARP Annual Meeting
Effective Treatment of TNFα Inhibitors in Chinese Patients with Blau Syndrome
Jing Chen ¹, Yi Luo ¹, Mengzhu Zhao ¹, Di Wu ¹, Yunjiao Yang ², Wen Zhang ³ and Min Shen¹, ¹Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ²Peking Union Medical College Hospital, Beijing, China (People's Republic), ³Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China (People's Republic)
Background/Purpose: Blau syndrome (BS) is a rare dominantly inherited autoinflammatory disorder associated with mutations in the NOD2 gene. BS is mainly seen in Caucasian patients.…
Abstract Number: 80 • 2017 Pediatric Rheumatology Symposium
Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades
Jennifer Rammel¹, Patricia Rosillo¹, Tiphanie Vogel² and Marietta de Guzman³, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Department of Pediatrics, Division of Immunology, Allergy and Rheumatology and the Center for Human Immunology at Texas Children's Hospital., Baylor College of Medicine, Houston, TX, ³Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Blau syndrome is a rare autoinflammatory granulomatous disease that presents with fever, arthritis, dermatitis and uveitis. It results from mutations in NOD2, an intracellular…
Abstract Number: 1134 • 2014 ACR/ARHP Annual Meeting
Role of NOD2 Pathway in Sarcoidosis Cases with Characteristics of Blau Syndrome
Gerard Dumancas¹, Indra Adrianto², Albert M. Levin³, Michael C. Iannuzzi⁴, Benjamin A. Rybicki³ and Courtney Montgomery⁵, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²825 Ne 13th St. Ms 57, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, ⁴Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Blau syndrome (BS) is a rare autosomal dominant, autoinflammatory syndrome characterized by the clinical triad symptoms of symmetric arthritis, dermatitis, and granulomatous recurrent uveitis,…
Abstract Number: 143 • 2014 ACR/ARHP Annual Meeting
Detailed Anatomical Distribution of Synovial Inflammation Revealed By Ultrasound in Patients with Blau Syndrome
Kei Ikeda¹, Naotomo Kambe², Syuji Takei^3,4, Taiji Nakano⁵, Yuzaburo Inoue⁵, Minako Tomiita⁶, Natsuko Oyake⁷, Takashi Satoh⁸, Tsuyoshi Yamatou³, Tomohiro Kubota³, Ikuo Okafuji⁹, Nobuo Kanazawa¹⁰, Ryuta Nishikomori¹¹, Naoki Shimojo⁵, Hiroyuki Matsue⁸ and Hiroshi Nakajima¹, ¹Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ²Dermatology, Chiba University Graduate School of Medicine, Chiba, Japan, ³Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ⁴School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁵Department of Pediatrics, Chiba University Graduate School of Medicine, Chiba, Japan, ⁶Department of Allergy and Rheumatology, Chiba Children’s Hospital, Chiba, Japan, ⁷Department of Pediatrics, Hitachinaka General Hospital, Hitachinaka, Japan, ⁸Department of Dermatology, Chiba University Graduate School of Medicine, Chiba, Japan, ⁹Department of Pediatrics, Kobe City Medical Center General Hospital, Kobe, Japan, ¹⁰Department of Dermatology, Wakayama Medical University, Wakayama, Japan, ¹¹Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose Arthritis is the most frequent manifestation of Blau syndrome, an autoinflammatory disorder caused by the genetic mutation of NOD2. However, the detailed information on…
Abstract Number: 2742 • 2013 ACR/ARHP Annual Meeting
Blau Syndrome-Associated NOD2 Mutations Limit Production Of IL-6 and KC/IL-8 In Knock-In Mice and In Patients Suggesting a Loss Of Function Disease Mechanism
Jae Dugan¹, Eric Griffiths¹, Paige Snow¹, Holly L. Rosenzweig¹, Carlos D. Rose², Daniel Carr¹, James T. Rosenbaum³ and Michael Davey¹, ¹Dept. of Veterans Affairs Medical Center, Portland, OR, ²Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, ³Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR
Background/Purpose: Blau syndrome is an autosomal dominant disorder caused by mutations in nucleotide-binding oligomerization domain 2 (Nod2) and characterized by arthritis, dermatitis and uveitis. Nod2…
Abstract Number: 1202 • 2013 ACR/ARHP Annual Meeting
Two Family Kindreds With Blau’s Syndrome Associated With Unusual NOD2 Mutations
Qingping Yao, Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Background/Purpose: The aim of this study was to report families of Blau’s syndrome with unusual NOD2 gene variants. Methods: Two proband patients were seen, and their clinical…
Abstract Number: 227 • 2013 ACR/ARHP Annual Meeting
Quantitative Image Analysis Of Articular Involvement In Blau Syndrome By Radiographic Calpal Length and Ultrasound Assessment
Tsuyoshi Yamatou¹, Tomohiro Kubota², Harumi Akaike¹, Yuichi Yamasaki², Yukiko Nonaka¹, Yasuhito Nerome¹, Tomoko Takezaki¹, Hiroyuki Imanaka¹, Kei Ikeda³, Naotomo Kambe⁴, Syuji Takei⁵ and Tomokazu Nagakura⁶, ¹Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ²Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ³Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁴Dermatology, Chiba University Graduate School of Medicine, Chiba, Japan, ⁵School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁶Department of Pediatrics, House of Meguminoseibo, Usuki, Japan
Background/Purpose: Blau syndrome (Blau) is a rare auto-inflammatory disease, and it has now been shown to be caused by NOD2/CARD15 gene mutations. Clinical features of…
Abstract Number: 191 • 2012 ACR/ARHP Annual Meeting
Analysis of Genes Involved in Autoinflammatory Diseases in Adult Onset Still’s Disease
Emma Garcia-Melchor¹, Dolors Grados², Eva Gonzalez-Roca¹, Elena Riera³, Manel Juan¹, Jordi Yagüe¹, Juan Ignacio Aróstegui¹, Javier Narváez⁴ and Alejandro Olivé⁵, ¹Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ³Rheumatology Department, Hospital Mutua de Terrassa, Terrassa, Spain, ⁴Rheumatology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁵Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Adult Onset Still’s Disease (AOSD) is a systemic inflammatory disease characterized by fever, skin rash, articular involvement, lymphadenopathy, hepatosplenomegaly and serositis. Due to the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].